A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...
Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...
With the Sebring on the way out, convertible buyers will enjoy the new 200 for its brand-new stylish look, low price and solid feature list. Base prices are expected to start under $20,000, and such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results